Resistance mechanisms and countermeasures in CLDN18.2-positive tumors: from molecular networks to clinical practice. (PubMed, Front Oncol) - Sep 11, 2026 - "Zolbetuximab, the first anti-CLDN18.2 antibody, was approved in 2024 for HER2-negative, CLDN18.2-high advanced gastric and gastro-esophageal junction adenocarcinoma, and more than one hundred CLDN18.2-directed trials are now under way across monoclonal antibodies, antibody-drug conjugates, bispecific antibodies and CAR-T cells...For patients with high, homogeneous baseline expression, an early intensive induction followed by CLDN18.2-directed maintenance may therefore be preferable to indefinite target-plus-chemotherapy. We further consider the tissue-context-dependent biology of CLDN18.2 relevant to patient selection, and outline the prospective, biomarker-embedded trials needed to test these proposals."
IO biomarker • Journal • Review • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor • CLDN18 • HER-2
|
|
Kai Sun; Mingfang Wang; Peng Wang; Taosheng Huang; Yutao Xia
|